Leerink Partnrs Estimates PureTech Health FY2024 Earnings

PureTech Health plc (NASDAQ:PRTC - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2024 earnings per share estimates for shares of PureTech Health in a note issued to investors on Tuesday, November 19th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings per share of ($4.31) for the year, down from their previous forecast of ($4.27). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for PureTech Health's current full-year earnings is ($4.32) per share.

Separately, Leerink Partners initiated coverage on PureTech Health in a research report on Monday, September 9th. They issued an "outperform" rating and a $45.00 price objective on the stock.

PureTech Health Price Performance

Shares of PRTC stock traded up $0.09 during trading hours on Thursday, reaching $21.78. The company's stock had a trading volume of 1,924 shares, compared to its average volume of 4,103. PureTech Health has a one year low of $17.08 and a one year high of $34.00. The firm's fifty day simple moving average is $20.53 and its 200 day simple moving average is $23.36.

Institutional Investors Weigh In On PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. AWM Investment Company Inc. purchased a new stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,900 shares of the company's stock, valued at approximately $197,000. 0.04% of the stock is currently owned by hedge funds and other institutional investors.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.